Intestinal dysbiosis in RA development: difficulty of establishing causality. Response to: 'Non-causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation study' by Inamo

We are grateful to Dr Inamo¹ for his interest in our article. We agree and acknowledged in our manuscript that our study design did not allow us to assess a causal association. Our study described an increased relative abundance in *Prevotella* spp. in individuals in 'preclinical rheumatoid arthritis (RA) stages' using participants enrolled in a first-degree relatives of patients with RA (FDR-RA) cohort.² The microbiota of individuals in preclinical RA stages were significantly altered compared with FDR-RA controls. In particular, bacteria of the Prevotellaceae family and associated taxa were enriched among individuals in preclinical stages of RA.

Dr Inamo concludes from his analysis that intestinal dysbiosis is probably only secondary phenomenon and unlikely to trigger the pathogenesis of RA. We respectfully disagree with this conclusion for several reasons:

- As Inamo points out, it is indeed impossible to make causal inferences from cross-sectional studies. Furthermore, the author rightfully notices that the scientific community still does not know whether 'dysbiosis comes first or RA comes first', which is precisely the reason we focused our analysis not on patients with RA but on individuals in different preclinical stages of the disease. While our findings are certainly not yet a proof for a causal role of intestinal dysbiosis in RA development, the demonstration of a large proportion of individuals in preclinical stages of RA with a significant dysbiosis is certainly consistent with the mucosal origins hypothesis of RA development.³
- Inamo used Mendelian randomisation analyses to assess causal association of dysbiosis with RA, taking advantage of two large datasets of genome-wide association studies (GWASs).^{4 5} Inamo obtained 26 SNPs from gut microbiome GWASs associated with reduced bacterial taxa (see online supplementary table 1, Inamo's correspondence letter). However, recent data strongly suggest only a minor influence of genetics on microbiota composition.⁶ Furthermore, no studies have ever found significant differences in alpha or beta diversities between RA cases and controls, despite significant differences in specific bacterial taxa (ie, Prevotella copri).2 7 Thus, the exposure analysed by the author does not represent a relevant measure of dysbiosis in RA. It would have been more appropriate for Inamo to analyse, for instance, Prevotella spp. abundance instead of reduced bacterial taxa.

To formally establish a causal role of intestinal dysbiosis in RA development, longitudinal studies prior to the onset of RA are required to demonstrate that specific dysbiosis precedes the development of RA, which then would have to be further validated by relevant *in vivo* studies and microbiome-centred intervention trials.

Deshire Alpizar Rodriguez ⁶, ¹ Till Robin Lesker, ² Benoît Gilbert, ¹ Till Strowig, ^{2,3} Axel Finckh ¹

¹Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland ²Department of Microbial Immune Regulation, Helmholtz Centre for Infection Research, Braunschweig, Germany

³Hannover Medical School, Hannover, Germany

Correspondence to Dr Deshire Alpizar Rodriguez, Division of Rheumatology, Department of Internal Medicine Specialties, University Hospitals of Geneva, 1205 Genève, Switzerland; deshire_alpizar@hotmail.com

Contributors DAR, TRL, BG, AF and TS were involved in writing the manuscript and approved the final version. All the authors had full access to all the data in the study and had the final responsibility for the decision to submit for publication.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.



To cite Alpizar Rodriguez D, Lesker TR, Gilbert B, et al. Ann Rheum Dis Epub ahead of print: [please include Day Month Year]. doi:10.1136/annrheumdis-2019-216637

Received 12 November 2019 Accepted 17 November 2019



► http://dx.doi.org/10.1136/annrheumdis-2019-216565

Ann Rheum Dis 2019;0:1. doi:10.1136/annrheumdis-2019-216637

ORCID in

Deshire Alpizar Rodriguez http://orcid.org/0000-0002-6930-0517

REFERENCES

- 1 Inamo J. Non-causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation study. Ann Rheum Dis 2019:annrheumdis-2019-216565.
- 2 Alpizar-Rodriguez D, Lesker TR, Gronow A, et al. Prevotella copri in individuals at risk for rheumatoid arthritis. Ann Rheum Dis 2019;78:590–3.
- 3 Holers VM, Demoruelle MK, Kuhn KA, et al. Rheumatoid arthritis and the mucosal origins hypothesis: protection turns to destruction. Nat Rev Rheumatol 2018:14:542–57.
- 4 Wang J, Thingholm LB, Skiecevičienė J, et al. Genome-Wide association analysis identifies variation in vitamin D receptor and other host factors influencing the gut microbiota. Nat Genet 2016:48:1396–406.
- 5 Okada Y, Wu D, Trynka G, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 2014;506:376–81.
- 6 Rothschild D, Weissbrod O, Barkan E, et al. Environment dominates over host genetics in shaping human gut microbiota. *Nature* 2018;555:210–5.
- 7 Kishikawa T, Maeda Y, Nii T, et al. Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population. Ann Rheum Dis 2019. doi:10.1136/annrheumdis-2019-215743. [Epub ahead of print: 07 Nov 2019].

